All In Biotech

Drug Trial Radar · NCT05117710

IMPase in Treatment-resistant Depression

Does the IMPase Inhibitor, Ebselen, Affect Emotional Processing and Brain Myo-inositol in Treatment-resistant Depression?

Last checked: Nov 19, 2026Latest source record: Jul 6, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

50

Planned (sponsor's estimate)

Start

Apr 22, 2021

Primary completion

May 31, 2024

Study completion May 31, 2024

Sponsor

Lead sponsor
University of OxfordAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Medical Research Council; Sound Pharmaceuticals, Incorporated
First posted
Nov 11, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Basic science
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This experimental medicine study will examine the effects of a brief period (seven days) of 'add on' ebselen (SPI-105) treatment in patients with resistant depression to see if ebselen produces changes in emotional responses consistent with a potential clinical antidepressant effect. The investigators will also seek to confirm ebselen's mode of action on IMPase by measuring changes in a brain chemical called inositol, using a magnetic imaging method. Half of the participants will receive ebselen and the other half placebo.

Conditions

  • Depressive Disorder, Treatment-Resistant

Interventions

  • EbselenDrug

    Ebselen is an organoselenium compound, developed originally as an antioxidant for use in neuroprotection, post-stroke. Ebselen is a bioavailable and brain penetrant inhibitor of inositol monophosphatase (IMPase) (Ki ≈ 1 μM).

  • PlaceboDrug

    Matched placebo capsules

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in positive and negative facial expression recognition taskTime frame: Change between groups from baseline to day 7
  2. Change in misclassifications on emotional processing taskTime frame: Change between groups from baseline to day 7
  3. Change in reaction time on emotional processing taskTime frame: Change between groups from baseline to day 7

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Neurosciences Building, Dept. Psychiatry, Warneford Hospital

    Oxford, Oxfordshire, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.